Infectious Disease Therapeutics Market Size and Forecasts (2020 - 2030), Global and Regional Share, Trends, and Growth Opportunity Analysis

The infectious disease therapeutics market size was valued US$ 1,19,708.77 million in 2022 and is expected to reach US$ 1,67,883.93 million by 2030; the market is estimated to record a CAGR of 4.30%  during 2022–2030.

Market Insights and Analyst View:

The infectious disease therapeutics market forecast can help stakeholders in this marketplace plan their growth strategies.  

Infectious diseases can transfer from one person to another through direct or indirect contact. Patients must take medications with anti-infective properties in order to treat infectious diseases. Pathogens such as bacteria, fungi, viruses, and parasites are the primary cause of these disorders. In order to target the organism causing the sickness and implement a remedy, the host's defensive system is directly targeted.

Growth Drivers:

Infectious diseases are caused by viruses, parasites, bacteria, fungi, toxic products, and other infectious agents. HIV is a major public health issue across the world. According to The Joint United Nations Programme on HIV/AIDS (UNAIDS), in 2020, ~ 37.7 million people had HIV. Out of these, 36 million were adults, and 1.7 million were children aged 0–14 years. Also, more than half (53%) were girls and women. Moreover, 1.5 million new HIV cases were reported in 2020 globally. Similarly, hepatitis is an infection of the liver caused by a viral infection. The main types of hepatitis viruses are A, B, C, D, and E. According to the World Health Organization (WHO), globally, ~ 58 million people are suffering from chronic hepatitis C virus infection, and every year, ~1.5 million new infections occur.

According to WHO, tuberculosis (TB) is the 13th top cause of death globally and the second leading infectious disease after COVID-19. In 2020, 1.5 million deaths were caused by TB (including 214,000 people affected by HIV). Furthermore, 10 million people had TB globally in 2020, including 1.1 million children, 3.3 million women, and 5.6 million men. Moreover, hospital-acquired infections or healthcare-associated infections (HAIs) have a high morbidity and mortality rate. Also, the expenditure on the healthcare system is huge every year. The Centers for Disease Control and Prevention (CDC) reported that HAIs account for ~1.7 million infection cases and 99,000 deaths every year in American hospitals. Therefore, the rising prevalence of infectious diseases across the globe is likely to drive the growth of the infectious disease therapeutics market size.  

Customize Research To Suit Your Requirement

We can optimize and tailor the analysis and scope which is unmet through our standard offerings. This flexibility will help you gain the exact information needed for your business planning and decision making.

Get 10% FREE CUSTOMIZATION

Infectious Disease Therapeutics Market: Strategic Insights

Market Size Value in	US$ 1,19,708.77 million in 2022
Market Size Value by	US$ 1,67,883.93 million by 2030
Growth rate	CAGR of 4.30% from 2022 to 2030
Forecast Period	2022-2030
Base Year	2022

Akshay

Have a question?

Akshay will walk you through a 15-minute call to present the report’s content and answer all queries if you have any.

 Speak to Analyst

Report Segmentation and Scope:

The infectious disease therapeutics market forecast involves the segmentation of the market based on drug class, indication, route of administration, and distribution channel. The infectious disease therapeutics market, by drug class, is sub-segmented into anti-viral, anti-bacterial, anti-fungal, and others. Further, the anti-viral segment held the largest market share in 2022; the anti-bacterial segment is predicted to register the highest CAGR in the market during the forecast period. Based on indication, the infectious disease therapeutics market is segmented into HIV, hepatitis, tuberculosis, influenza, HPV, and others. The HIV segment held the largest market share in 2022 and is predicted to register the highest CAGR during 2022–2030. In terms of route of administration, the infectious disease therapeutics market is segmented into oral, parenteral, topical, and others. The oral segment held the largest market share in 2022 and is anticipated to register highest CAGR during 2022–2030. The infectious disease therapeutics market, by distribution channel, is categorized into hospital pharmacies, retail pharmacies, and others. The hospital pharmacies segment held the largest market share in 2022 and is anticipated to register highest CAGR during 2022–2030.

Segmental Analysis:

The infectious disease therapeutics market, by drug class, is segmented into anti-viral, anti-bacterial, anti-fungal, and others. The anti-viral segment held the largest share of the market in 2022; the anti-bacterial segment is projected to register the highest CAGR in the market during 2022–2030.

Anti-viral agents are drugs approved by the US Food and Drug Administration (FDA) for treating viral infections. Anti-viral agents typically target distinct phases of the viral life cycle. Anti-viral medications can be used for the prevention, treatment, and suppression of overt diseases. Several strategies are used to develop anti-viral agents, including direct-acting anti-virals targeting enzymes, viral proteins, or nucleic acids; passive antibodies neutralizing circulating viruses; and drugs targeting cellular proteins or processes essential for viral replication. Half of the currently offered anti-viral agents are used for the purpose of treating human immunodeficiency virus (HIV) infections. The other drugs are primarily used to treat herpes viruses, hepatitis B, hepatitis C, and respiratory viruses. For instance, as per the WHO statistics, in 2019, there were 690,000 deaths due to HIV globally, recording 1.7 million new cases of HIV infection, with overall cases of ~38 million. Thus, the above mentioned factors is likely to favor the infectious disease therapeutics market growth.

Infectious Disease Therapeutics Market, by Drug Class – 2022 and 2030

By indication, the infectious disease therapeutics market is segmented into HIV, hepatitis, tuberculosis, influenza, HPV, and others. The HIV segment held the largest share of the market in 2022 and is anticipated to register the highest CAGR in the market during 2022–2030. HIV weakens an individual’s immune system by destroying important cells that fight disease and infection. Due to various factors, including sexual partners and risky behaviors, some groups of people in the US are more likely to contract HIV than others. The risk of getting an infection after surgery can rise due to growing immune system suppression by HIV. The number of patients with HIV infection has been steadily rising in recent years. The life expectancy of HIV infection and AIDS patients has significantly increased since the introduction of antiretroviral therapy (ART). Thus, with the continuous rise in the need for surgical care and the prevalence of surgical diseases that result from HIV infection, the market for infectious disease therapeutics is expected to grow during the forecast period.

The infectious disease therapeutics market analysis, by route of administration has been carried out by considering the following segments: oral, parenteral, topical, and others. The oral segment held the largest share of the market in 2022 and is anticipated to register the highest CAGR in the infectious disease therapeutics market during 2022-2030. According to the NIH report, oral administration of anti-infectives is a convenient, cost-effective, and most commonly used route of administration among patients. Furthermore, the oral route of administration for anti-infectives is prescribed more often than the parenteral/intravenous route. For example, major advantages associated with the oral route involve the absence of cannula-related infections or thrombophlebitis, a low drug cost, and reduced hidden costs such as less need for health professionals and equipment for administering intravenous anti-infectives. The Frontiers SA report states that ~60% of commercially established anti-infective products are administered orally. Moreover, oral anti-infective formulations represent ~90% of the global market share in pharmaceutical formulations for patient use.

By distribution channel, the infectious disease therapeutics market is segmented into hospital pharmacies, retail pharmacies, and others. In 2022, in terms of revenue, hospital pharmacies dominated the global infectious disease therapeutics market share.

Hospital pharmacies work to consistently uphold and improve medication management to the utmost standards in a hospital setting. Hospital pharmacies are one of the primary areas in hospitals where various pharmaceutical products are stored, purchased, compounded, dispensed, and distributed. Overseeing the usage of pharmaceuticals in hospitals and medical facilities is one of the main responsibilities of hospital pharmacies. The selection, procurement, delivery, administration, and review of pharmaceutical products are among the objectives of the hospital pharmacies that aim toward improving patient outcomes. 

Regional Analysis:

Geographically, the global infectious disease therapeutics market is segmented into North America, Europe, Asia Pacific, South & Central America, and the Middle East & Africa. In 2022, in terms of revenue, North America dominated the global infectious disease therapeutics market share.  Factors such as growing demand for advanced therapeutic solutions to treat infectious diseases and rising research and development activities propel the infectious disease therapeutics market growth in the region.

Asia Pacific is expected to register the highest CAGR during 2022–2030. The infectious disease therapeutics market in the region is expected to grow owing to rising global healthcare expenditure, increasing incidence of chronic and infectious diseases, and a growing geriatric population base. Infectious diseases such as influenza, hepatitis B, and infectious diarrhea are common in China, while there is a high prevalence of typhoid, malaria, jaundice, tuberculosis, and AIDS in India.

Access Data

Industry Developments and Future Opportunities:

The growing incidence of infectious diseases is anticipated to increase the sales of infectious disease therapeutics drugs in developing countries. Asia Pacific has become an adaptable and business-friendly hub due to moderately fewer data requirements and stringent regulations. In addition, high investments in health research and life science in emerging countries play a key role in promoting the latest technologies in developing countries, which, in turn, supports the inclination toward infectious disease diagnosis and treatment. For instance, UNAIDS is advocating for an investment of US$ 29 billion by 2025 to meet the needs of low- and middle-income countries in order to prevent and treat AIDS. In India, South Korea, Brazil, and Mexico, there is a high prevalence of infectious diseases such as Hepatitis, HAI, HIV, and influenza; a large population of patients; a rise in disposable income of the population; improved infrastructure of healthcare; and growing medical tourism. Thus, crucial infectious disease therapeutics product manufacturers in emerging infectious disease therapeutics markets in these countries are expected to witness lucrative opportunities in the future.

Competitive Landscape and Key Companies:

Pfizer Inc, Gilead Sciences Inc, F. Hoffmann-La Roche Ltd, Shionogi & Co Ltd, Bayer AG, BioCryst Pharmaceuticals Inc, GSK Plc, AbbVie Inc, Merck & Co Inc, and Astellas Pharma Inc are the prominent players profiled in infectious disease therapeutics market report. These companies focus on new technologies, upgrading existing products, and geographic expansions to meet the growing consumer demand worldwide.